KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner

Qian, Jiayi; Gao, Jian; Sun, Xi; Cao, Mengda; Shi, Liang; Xia, Tiansong; Zhou, Wenbin; Wang, Shui; Ding, Qiang; Wei, Ji‐Fu

doi:10.1038/s41388-019-0861-z

Cited by 171 publications

(216 citation statements)

References 56 publications

Supporting

Mentioning

195

Contrasting

Order By: Relevance

“…The levels of m6A modification in mRNAs were usually controlled by so‐called ‘reader’, ‘writer’ and ‘eraser’ . The ‘writer’, which is a high conserved methylase complex, containing methyltransferase like 3 (METTL3), methyltransferase like 14, Wilms’ tumour 1‐associating protein, RNA‐binding motif protein 15, Vir like m6A methyltransferase associated, Fl(2)d‐associated complex component and Hakai…”

Section: Introductionmentioning

confidence: 99%

“…15 The levels of m6A modification in mRNAs were usually controlled by so-called 'reader', 'writer' and 'eraser'. 16,17 The 'writer', which is a high conserved methylase complex, containing methyltransferase like 3 (METTL3), 18 methyltransferase like 14, 18 Wilms' tumour 1-associating protein, 19 RNA-binding motif protein 15,20,21 Vir like m6A methyltransferase associated, 18,22 Fl(2)d-associated complex component 20 and Hakai. 23 Recent studies showed that m6A modification played essential roles in tissue development, stem cell formation and differentiation, 24,25 control of heat shock response 26 and circadian clock controlling, 27 as well as in tumours formation.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Methyltransferase like 3 promotes colorectal cancer proliferation by stabilizing CCNE1 mRNA in an m6A‐dependent manner

Zhu

et al. 2020

J Cellular Molecular Medi

Self Cite

View full text Add to dashboard Cite

m6A modification is the most prevalent RNA modification in eukaryotes. As the critical N6‐methyladenosine (m6A) methyltransferase, the roles of methyltransferase like 3 (METTL3) in colorectal cancer (CRC) are controversial. Here, we confirmed that METTL3, a critical m6A methyltransferase, could facilitate CRC progression in vitro and in vivo. Further, we found METTL3 promoted CRC cell proliferation by methylating the m6A site in 3′‐untranslated region (UTR) of CCNE1 mRNA to stabilize it. Moreover, we found butyrate, a classical intestinal microbial metabolite, could down‐regulate the expression of METTL3 and related cyclin E1 to inhibit CRC development. METTL3 promotes CRC proliferation by stabilizing CCNE1 mRNA in an m6A‐dependent manner, representing a promising therapeutic strategy for the treatment of CRC.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Methyltransferase like 3 promotes colorectal cancer proliferation by stabilizing CCNE1 mRNA in an m6A‐dependent manner

Zhu

et al. 2020

J Cellular Molecular Medi

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, Cheng et al [27] reported that KIAA1429 inhibits ID2 by increasing the m 6 A modification of ID2 mRNA, thus promoting HCC migration and invasion. Additionally, Qian and colleagues [24] reported that KIAA1429 can regulate CDK1 in breast cancer in an m 6 A-independent manner, and act as a carcinogenic factor. These studies suggest that KIAA1429 promotes tumorigenesis and development.…”

Section: Discussionmentioning

confidence: 99%

“…The main role of YTHDF2 is to regulate the degradation of m 6 A-modified mRNAs [24]. However, the relationship between YTHDF2 and cancer is largely unknown.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, m 6 A modifications direct mRNAs to different destinies through differential processing, translation, and decay during the stress response, embryonic development, and cell differentiation [19]. Increasing evidence has shown that genetic changes (e.g., copy number variation [CNV] and single-nucleotide polymorphism [SNP] mutations) and expression disorders related to m 6 A RNA methylation modulators are closely related to the malignant progression of various cancers [20][21][22][23][24]. Many studies have pointed out that abnormal m 6 A modification is associated with HCC progression [20,[25][26][27][28][29].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Multiple m6A RNA methylation modulators promote the malignant progression of hepatocellular carcinoma and affect its clinical prognosis

Qin

Zhang

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death in the world. N 6 -methyladenosine (m 6 A) RNA methylation is dynamically regulated by m 6 A RNA methylation modulators ("writer," "eraser," and "reader" proteins), which are associated with cancer occurrence and development. The purpose of this study was to explore the relationships between m 6 A RNA methylation modulators and HCC. Methods: First, using data from The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) databases, we compared the expression levels of 13 major m6A RNA methylation modulators between HCC and normal tissues. Second, we applied consensus clustering to the expression data on the m 6 A RNA methylation modulators to divide the HCC tissues into two subgroups (clusters 1 and 2), and we compared the clusters in terms of overall survival (OS), World Health Organization (WHO) stage, and pathological grade. Third, using least absolute shrinkage and selection operator (LASSO) regression, we constructed a risk signature involving the m 6 A RNA methylation modulators that affected OS in TCGA and ICGC analyses. Results: We found that the expression levels of 12 major m6A RNA methylation modulators were significantly different between HCC and normal tissues. After dividing the HCC tissues into clusters 1 and 2, we found that cluster 2 had poorer OS, higher WHO stage, and higher pathological grade. Four m 6 A RNA methylation modulators (YTHDF1, YTHDF2, METTL3, and KIAA1429) affecting OS in the TCGA and ICGC analyses were selected to construct a risk signature, which was significantly associated with WHO stage and was also an independent prognostic marker of OS. Conclusions: In summary, m 6 A RNA methylation modulators are key participants in the malignant progression of HCC and have potential value in prognostication and treatment decisions.

show abstract

Systematic expression analysis of m⁶A RNA methyltransferases in clear cell renal cell carcinoma

et al. 2021

View full text Add to dashboard Cite

Objectives To investigate the regulation of the N‐6‐methyladenosine (m6A) methyltransferases METTL3, METTL14, WTAP, KIAA1429, and METTL4, referred to as “m6A writers,” in clear cell renal cell carcinoma (ccRCC), and other RCC subtypes in respect of the potential prognostic value. Patients and methods Tissue samples were collected within the framework of the Biobank at the Center for Integrated Oncology Bonn. The expression of the methyltransferases was systematically determined in clear cell renal carcinoma (ccRCC) on the RNA (real‐time PCR) and protein level (immunohistochemistry). Additionally, protein expression of the m6A writers was further investigated in papillary RCC, chromophobe RCC, sarcomatoid RCC, oncocytoma, and normal renal tissue (immunohistochemistry). Results The expression of all m6A‐methyltransferases was significantly downregulated in ccRCC compared to benign renal tissue. Low m6A‐methyltransferase levels were correlated with higher histological grade, advanced pT‐stage, pN‐stage, and metastatic disease. Reduced m6A‐methyltransferase expression was associated with shorter overall survival. Conclusion In conclusion, m6A‐methyltransferases are dysregulated in ccRCC and might act as tumor suppressor genes, which could be of particular importance for future diagnostic and therapeutic options.

show abstract

KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner

Cited by 171 publications

References 56 publications

Methyltransferase like 3 promotes colorectal cancer proliferation by stabilizing CCNE1 mRNA in an m6A‐dependent manner

Methyltransferase like 3 promotes colorectal cancer proliferation by stabilizing CCNE1 mRNA in an m6A‐dependent manner

Multiple m6A RNA methylation modulators promote the malignant progression of hepatocellular carcinoma and affect its clinical prognosis

Systematic expression analysis of m⁶A RNA methyltransferases in clear cell renal cell carcinoma

Contact Info

Product

Resources

About

KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner

Cited by 171 publications

References 56 publications

Methyltransferase like 3 promotes colorectal cancer proliferation by stabilizing CCNE1 mRNA in an m6A‐dependent manner

Methyltransferase like 3 promotes colorectal cancer proliferation by stabilizing CCNE1 mRNA in an m6A‐dependent manner

Multiple m6A RNA methylation modulators promote the malignant progression of hepatocellular carcinoma and affect its clinical prognosis

Systematic expression analysis of m6A RNA methyltransferases in clear cell renal cell carcinoma

Contact Info

Product

Resources

About

Systematic expression analysis of m⁶A RNA methyltransferases in clear cell renal cell carcinoma